Page last updated: 2024-08-23

simvastatin and Atrophy

simvastatin has been researched along with Atrophy in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alexander, DC; Barkhof, F; Cardoso, MJ; Chan, D; Chataway, J; Ciccarelli, O; Eshaghi, A; Greenwood, J; Kievit, RA; Nicholas, J; Nicholas, R; Ourselin, S; Prados, F; Sudre, CH; Thompson, AJ	1
Alsanousi, A; Anderson, V; Bangham, CR; Calder, VL; Chan, D; Chataway, J; Clegg, S; Fox, NC; Frost, C; Greenwood, J; Hunter, K; MacManus, D; Nicholas, JM; Nicholas, R; Nielsen, C; Schuerer, N; Wilkie, D	1
Granger, DN; Jin, R; Li, G; Liu, L; Nanda, A; Zhu, X	1

Trials

1 trial(s) available for simvastatin and Atrophy

Article	Year
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet (London, England), 2014, Jun-28, Volume: 383, Issue:9936 Topics: Administration, Oral; Adolescent; Adult; Aged; Atrophy; Brain; Cytokines; Disabled Persons; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Simvastatin; Young Adult	2014

Article

Year

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.

Lancet (London, England), 2014, Jun-28, Volume: 383, Issue:9936

Topics: Administration, Oral; Adolescent; Adult; Aged; Atrophy; Brain; Cytokines; Disabled Persons; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Simvastatin; Young Adult

2014

Other Studies

2 other study(ies) available for simvastatin and Atrophy

Article	Year
Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 05-28, Volume: 116, Issue:22 Topics: Adult; Atrophy; Brain; Causality; Cholesterol; Clinical Trials as Topic; Disease Progression; Humans; Middle Aged; Models, Statistical; Multiple Sclerosis, Chronic Progressive; Simvastatin	2019
Simvastatin attenuates stroke-induced splenic atrophy and lung susceptibility to spontaneous bacterial infection in mice. Stroke, 2013, Volume: 44, Issue:4 Topics: Animals; Anticholesteremic Agents; Apoptosis; Atrophy; Bacterial Infections; bcl-2-Associated X Protein; Brain Infarction; Disease Models, Animal; Humans; Infarction, Middle Cerebral Artery; Infections; Interferon-gamma; Lung; Mice; Mice, Inbred C57BL; Proto-Oncogene Proteins c-bcl-2; Simvastatin; Spleen; Splenectomy; Stroke	2013

Article

Year

Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis.

Proceedings of the National Academy of Sciences of the United States of America, 2019, 05-28, Volume: 116, Issue:22

Topics: Adult; Atrophy; Brain; Causality; Cholesterol; Clinical Trials as Topic; Disease Progression; Humans; Middle Aged; Models, Statistical; Multiple Sclerosis, Chronic Progressive; Simvastatin

2019

Simvastatin attenuates stroke-induced splenic atrophy and lung susceptibility to spontaneous bacterial infection in mice.

Stroke, 2013, Volume: 44, Issue:4

Topics: Animals; Anticholesteremic Agents; Apoptosis; Atrophy; Bacterial Infections; bcl-2-Associated X Protein; Brain Infarction; Disease Models, Animal; Humans; Infarction, Middle Cerebral Artery; Infections; Interferon-gamma; Lung; Mice; Mice, Inbred C57BL; Proto-Oncogene Proteins c-bcl-2; Simvastatin; Spleen; Splenectomy; Stroke

2013